HSCS · HeartSciences Inc.
$3.12
+0.13 (+4.35%)
At close · Aug 27
Going-concern doubt
— flagged Jul 23, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our independent registered public accounting firm has issued an opinion on our audited financial statements included in this Annual Report on Form 10-K that contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern because we have experienced recurring losses, negative cash flows from operations, and limited capital resources. These events and conditions indicate that a material uncertainty exists that may cast significant doubt on our ability to continue as a going concern.”View the 10-K filed Jul 23, 2026
Market Cap
$12.17M
Shares
3.90M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Andrea Childs | director | Appointed | 2026-06-26 |
| Erik Ellingson | Chief Financial Officer | Appointed | 2026-06-26 |
| Andrea Childs | Chief Executive Officer | Appointed | 2026-06-26 |
| Erik Ellingson | Chief Financial Officer | Appointed | 2026-06-23 |
| Andrea Childs | Chief Executive Officer | Appointed | 2026-06-23 |
| David R. Wells | Board of Directors | Appointed | 2023-03-16 |
| David R. Wells | Director | Appointed | 2023-01-03 |
| Patrick Kanouff | Director | Resigned | 2023-01-03 |
Key facts
CIK
1468492
CUSIP
42254E302
13F (30d)
15 filings
15 filers
Visit website
Investor relations